|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400094004 |
|
最近更新日期: Date of Last Refreshed on: |
2024-12-16 11:22:00 |
|
注册时间: Date of Registration: |
2024-12-16 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
短时程脊髓电刺激联合免疫三氧大自血治疗中老年带状疱疹后神经痛的前瞻性、随机、对照研究 |
|
Public title: |
A prospective, randomized and controlled study of short-term spinal cord electrical stimulation combined with Ozonated Autohemotherapy in the treatment of postherpetic neuralgia in middle-aged and elderly patients |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
短时程脊髓电刺激联合免疫三氧大自血治疗中老年带状疱疹后神经痛的前瞻性、随机、对照研究 |
|
Scientific title: |
A prospective, randomized and controlled study of short-term spinal cord electrical stimulation combined with Ozonated Autohemotherapy in the treatment of postherpetic neuralgia in middle-aged and elderly patients |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
黄翔 |
研究负责人: |
黄翔 |
|
Applicant: |
Huang Xiang |
Study leader: |
Huang Xiang |
|
申请注册联系人电话: Applicant telephone: |
+86 180 3886 2234 |
研究负责人电话: Study leader's telephone: |
+86 180 3886 2234 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
leohuangxiang@163.com |
研究负责人电子邮件: Study leader's E-mail: |
leohuangxiang@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广东省佛山市第一人民医院疼痛科 |
研究负责人通讯地址: |
广东省佛山市第一人民医院疼痛科 |
|
Applicant address: |
Department of Pain The First Peoples Hospital of Foshan Guangdong Province |
Study leader's address: |
Department of Pain The First Peoples Hospital of Foshan Guangdong Province |
|
申请注册联系人邮政编码: Applicant postcode: |
528000 |
研究负责人邮政编码: Study leader's postcode: |
528000 |
|
申请人所在单位: |
佛山市第一人民医院 |
||
|
Applicant's institution: |
The First Peoples Hospital of Foshan |
||
|
研究负责人所在单位: |
佛山市第一人民医院 |
||
|
Affiliation of the Leader: |
The First Peoples Hospital of Foshan |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦审研(2024)第140号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
佛山市第一人民医院伦理委员会 |
||
|
Name of the ethic committee: |
Foshan First People's Hospital Ethics Committee |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-11-25 00:00:00 |
||
|
伦理委员会联系人: |
何艳阳 |
||
|
Contact Name of the ethic committee: |
He yan yang |
||
|
伦理委员会联系地址: |
广东省佛山市禅城区岭南大道北81号 |
||
|
Contact Address of the ethic committee: |
No. 81, Lingnan Avenue North, Foshan City, Guangdong Province, China. |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 180 3886 6165 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
fsllwyh@fsyyy.com |
|
研究实施负责(组长)单位: |
佛山市第一人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Peoples Hospital of Foshan |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广东省佛山市禅城区岭南大道北81号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 81, Lingnan Avenue North, Foshan City, Guangdong Province, China. |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
佛山市第一人民医院 |
||||||||||||||||||||||
|
Source(s) of funding: |
The First Peoples Hospital of Foshan Guangdong Province |
||||||||||||||||||||||
|
Target disease: |
post-herpetic neuralgia |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
旨在观察短时程脊髓电刺激技术(temporary spinal cord stimulation, tSCS)联合免疫三氧大自血治疗对中老年带状疱疹后神经痛(post-herpetic neuralgia, PHN)的镇痛效果,生活质量的改善,免疫力改变,进而综合评估tSCS联合免疫三氧大自血治疗中老年PHN的有效性及安全性。 |
||||||||||||||||||||||
|
Objectives of Study: |
The aim of this study was to observe the analgesic effect, improvement in quality of life, changes in immunity, and overall assessment of the efficacy and safety of temporary spinal cord stimulation (tSCS) combined with immunotherapy with high-concentration ozone autohemotherapy in the treatment of post-herpetic neuralgia (PHN) in middle-aged and elderly patients. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.符合PHN诊疗中国专家共识的诊断标准,出疹时间在1年之内 2.年龄在50-80岁以内的PHN疼痛患者,男女不限 3.出疹部位除头面部之外,所有躯干四肢部位脊神经支配(C4-L5) 4.口服普瑞巴林(150-300mg/d)VAS仍然>=4分,或者每日爆发痛≧3次的住院患者 5.完善神经病理性疼痛评估量表ID Pain、DN-4,考虑疼痛性质为神经病理性疼痛 6.受试者能遵医嘱执行药物以及手术治疗,接受访视计划;理解调查问卷内容,或者在访视人员的协助下可以完成调查问卷 7.无免疫三氧大自血禁忌症 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Meet the diagnostic criteria agreed upon by Chinese experts for the diagnosis and treatment of PHN, with a rash onset time within 1 year 2. PHN pain patients aged 50-80 years old, male or female, not limited 3. Except for the head and face, all trunk and limb areas have spinal nerve innervation (C4-L5) 4. Hospitalized patients with oral Pregabalin (150-300mg/d) VAS score>=4, or experiencing pain outbreaks ≥ 3 times a day 5. Improve the neuropathic pain assessment scale ID Pain DN-4, Consider the nature of the pain as neuropathic pain 6. The subjects are able to follow the doctor's instructions for medication and surgical treatment, and accept the visit plan; Understand the content of the survey questionnaire, or be able to complete the survey questionnaire with the assistance of the interviewer 7. No contraindications for autoimmune trioxides in the blood |
||||||||||||||||||||||
|
排除标准: |
1.一般情况差,或有严重全身性感染或HIV感染者,呼吸功能不全等不能主动配合 2.患有过敏性疾病、属过敏体质者 3.有研究药物结构相似(普瑞巴林、奥施康定)药物敏史 4.癫痫患者及有癫痫家族史者;存在严重消化性溃疡、胰腺炎、肠梗阻、哮喘等试验药物手术相关的禁忌证患者 5.怀疑或确有药物滥用病史的患者 6.实验前3个月内曾参加药物试验的患者(包括本试验药物) 7.合并神经系统其他疾病需要服用镇痛药物者 8.存在脊髓电刺激手术禁忌症 9.不能耐受置电极操作患者 10.严重精神类或其他疾病无法正确行疼痛评分或不能客观描述症状 11.无法按期随访 12.患有肿瘤疾病或者自身免疫疾病的患者 13.存在三氧大自血禁忌症,如蚕豆病;甲状腺功能亢进;凝血功能异常;严重心血管疾病不稳定期;贫血患者;孕妇尤其是孕早期患者;神经官能症等其他原因不明的疾病;应用血管紧张素转换酶抑制剂治疗患者;医用三氧过敏患者等。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. In general, if the situation is poor, or if there is a serious systemic infection or HIV infection, respiratory dysfunction, etc., it is not possible to cooperate actively 2. Individuals with allergic diseases and those with an allergic constitution 3. History of drug sensitivity to drugs with similar structures (Pregabalin, OxyContin) 4. Epilepsy patients and those with a family history of epilepsy; Patients with contraindications related to experimental drug surgery, such as severe peptic ulcer, pancreatitis, intestinal obstruction, asthma, etc 5. Patients who suspect or have a history of drug abuse 6. Patients who have participated in drug trials within 3 months prior to the experiment (including the investigational drug) 7. For those who need to take analgesic drugs due to the combination of other neurological diseases 8. Contraindications for spinal cord electrical stimulation surgery exist 9. Patients who cannot tolerate electrode placement operations 10. Severe mental or other illnesses that cannot be accurately rated for pain or cannot objectively describe symptoms 11. Unable to follow up on schedule 12. Patients with tumor diseases or autoimmune diseases 13. There are contraindications for high oxygen levels in the blood, such as favism; Hyperthyroidism; Abnormal coagulation function; Unstable period of severe cardiovascular disease; Anemic patients; Pregnant women, especially those in the early stages of pregnancy; Diseases of unknown causes such as neurosis; Use angiotensin-converting enzyme inhibitors to treat patients; Medical oxygen allergy patients, etc. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-10-01 00:00:00至 To 2026-10-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2024-12-16 00:00:00 至 To 2025-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由专职的统计学人员根据参考文献制定随机数字表,研究对象经过筛选后,根据随机数字表随机分配入组和编码。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
A dedicated statistician creates a random number table based on references, and after the study subjects have been screened, they are randomly assigned and coded using the random number table. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
单盲 |
|
Blinding: |
single-blind |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病历记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |